Site last updated on: Feb. 9, 2010
 
Advanced Search
 Clinical Management Series
Natural Medicines in Clinical Management
of Depression
Treatment | Neurotransmitter Modulators | Neurotransmitter Precursors
Omega-3 Fatty Acids | Hormonal Agents | Nutrients
Miscellaneous | The Bottom Line | References
 
Depression is the second most common medical condition seen in general medical practice. Only hypertension is more common. In the U.S., about 16% of adults experience major depression during their lifetime. And less than 25% of depressed patients are adequately treated.10831,10832,10833

Depression is twice as common in women as it is in men. The highest rate of first time depression occurs in adolescents and young adults aged 12 to 24.10832,10833 Depression is the leading cause of death and disability for people aged 18 to 44. Depression commonly occurs along with conditions such as heart disease. In fact, patients with both heart disease AND depression are 4.5 times more likely to have a heart attack than non-depressed cardiac patients.10833,10835 Depression can also be fatal by itself...about 15% of depressed patients commit suicide.10834

Depression is thought to be due to altered neurochemistry. Three major neurotransmitters play a central role... norepinephrine, serotonin, and dopamine. Norepinephrine affects vigilance, motivation, and overall energy levels. In concert with serotonin, norepinephrine affects anxiety and irritability. Serotonin seems to control impulsivity. Serotonin, along with dopamine, regulates appetite, sex, and aggression.10833

Major depression is subclassified as mild, moderate, or severe depression. This division is based on the intensity of depressive symptoms and how impaired patients are by their depression.10831,10833 Dysthymia is a chronic, less severe form of depression. Dysthymia is defined by milder depressive symptoms that persist for 2 or more years.10831

Practice Pearl

Here's a quick way to screen for depression. Just ask these two questions.

  • "During the past month, have you often been bothered by feeling, down, depressed, or hopeless?"
  • "During the past month, have you often been bothered by having little interest or pleasure in doing things?"
If a patient answers "yes" to either question, it suggests a need for clinical followup.10831

Commonly Used Conventional and Natural Medicines for Depression*
Neurotransmitter Modulators
   Conventional Medicines
      Monoamine Oxidase Inhibitors (phenelzine,          tranylcypromine)
      Tricyclic Antidepressants (amitriptyline,          clomipramine, imipramine, etc)
      Serotonin Selective Reuptake Inhibitors          (fluoxetine, paroxetine, sertraline, etc)
      Miscellaneous (bupropion, mirtazapine,          venlafaxine, etc)
   Natural Medicines
      St. John's wort (Hypericum perforatum)
      SAMe (S-adenosylmethionine)
      Inositol
      NADH (nicotinamide adenine dinucleotide)
Neurotransmitter Precursors
   Phenylalanine
   Tyrosine
   L-tryptophan
   5-hydroxytryptophan (5-HTP)
   Phosphatidylserine
   Acetyl-L-carnitine
Essential Fatty Acids
   Omega-3 fatty acids (fish oils)
   Docosahexanoic acid (DHA)
   Eicosapentaenoic acid (EPA)
Hormonal Agents
   Dehydroepiandrosterone (DHEA)
   Pregnenolone
   Progesterone
Nutrients
   Multivitamins
   Vitamin C
   B vitamins
   Folic acid
Miscellaneous
   Damiana (Turnera diffusa)
   Ginkgo (Ginkgo biloba)
   Glutamine
   Lavender (Lavandula angustifolia)
   Turmeric (Curcuma longa)
   Yohimbe (Pausinystalia yohimbe)

*Note: Many natural products are tried for depression, but very few have reliable evidence that they work. Inclusion in this list does NOT imply that these products are effective for depression.
 

 
 
 
  Question #1
Which of the following is TRUE?
  • Treatmentreturn to top 

    Antidepressants are the treatment of choice for most patients with depression. More than 50% of depressed patients respond to initial treatment with conventional antidepressants.

     
    Neurotransmitter Modulatorsreturn to top 

    The newer selective serotonin reuptake inhibitors (SSRIs) are usually preferred. They are as effective as the older tricyclic antidepressants (TCAs), but cause fewer side effects. Both TCAs and some newer agents affect multiple neurotransmitters. For example, venlafaxine (Effexor) inhibits both serotonin and norepinephrine reuptake. Agents with such activity are often used in patients who don't respond to other antidepressants.

    Many natural products also seem to affect neurotransmitters and brain biochemistry and are therefore tried for depression. Lots of depressed patients turn to natural products.10841,10842 Over 50% try a natural product. Only HALF tell their physician.10842

    St. John's wort (Hypericum perforatum) is the most common supplement tried for depression. It works similarly to conventional antidepressants. St. John's wort inhibits the reuptake of serotonin, norepinephrine, and dopamine. It also appears to affect other neurochemicals...adenosine, benzodiazepine, and gamma-aminobutyric acid (GABA). It may even act as a weak monoamine oxidase inhibitor. The exact mechanism of St. John's wort for treating depression is unknown.763,4521,8936

    Many St. John's wort products are standardized to the component hypericin. But now researchers think the antidepressant activity is most likely due to other components ...hyperforin and adhyperforin.763,4521

    For MILD and MODERATE depression, most studies show St. John's wort is superior to placebo.4899,6428,9592 St. John's wort doesn't seem to help SEVERE depression.5096,10843 St. John's wort also appears to be as effective as low-dose TCAs for mild to moderate depression.3548,3549,3551,6434 And possibly as effective as the SSRIs fluoxetine (Prozac) and sertraline (Zoloft).3550,4897,6400 However, recently in two large trials, St. John's wort was no better than placebo.5096,10843 These trials were performed in psychiatry centers. Many St. John's wort trials are in primary care settings. Patient characteristics can be different in primary care settings versus psychiatric clinics. 11154

    Tell patients St. John's wort may help mild to moderate depression. The daily dose most commonly used is 300 mg three times daily.4899 The incidence of adverse effects in patients treated with St. John's wort is similar to placebo and less than conventional antidepressants.4899,10845 Sexual dysfunction is less frequent with St. John's wort than with SSRIs.10843

    Serotonin syndrome can occur with St. John's wort alone or when it's taken with other drugs that increase serotonin levels.542,6201 Hypertensive crisis has been reported in a patient taking St. John's wort and eating tyramine-containing food and red wine.7812 Tell patients not to combine St. John's wort with other antidepressants.

    Symptoms of
    Serotonin Syndrome10765,10766
    Agitation
    Confusion
    Hyperthermia
    Tachycardia
    Hypertension
    Exaggerated tendon reflexes

    St. John's wort is a potent inducer of cytochrome P450 3A4 (CYP3A4). St. John's wort also induces P-glycoprotein, a cellular pump that protects the body against foreign substances. P-glycoprotein can pump drug molecules out of a cell...reducing absorption.1340,7810 St. John's wort is also thought to induce CYP1A2 and CYP2C9.1292,3556 St. John's wort probably has little effect on CYP2D6.3599,4835,10830,10847,10848

    Practice Pearl

    Caution women taking St. John's wort and oral contraceptives to use an additional form of contraception. St. John's wort increases the metabolism of ethinyl estradiol and progestins. Breakthrough bleeding, irregular menstrual bleeding, and unintended pregnancy can occur when St. John's wort is taken with oral contraceptives.1292,7809,9880

    St. John's wort shows efficacy similar to conventional drugs for mild to moderate depression. But it can have a lot more drug interactions than many conventional antidepressants. Emphasize to patients the importance of telling ALL healthcare providers about their use of St. John's wort. Although St. John's wort might help, there are significant drug interactions and in most cases a conventional antidepressant is preferred.

    S-adenosylmethionine (SAMe) is an amino acid derivative synthesized in the body. SAMe is also available from protein sources, like meat. SAMe is used for both depression and osteoarthritis. SAMe works differently than most conventional antidepressants. It seems to increase dopamine and norepinephrine levels.5196,5232,9110

    SAMe appears to be about as effective as TCAs for treating depression.5189,5192,5193,5195,5200,9108,9109 There's no reliable evidence that SAMe treats depression faster than conventional antidepressants. SAMe is generally well-tolerated. It's been taken safely for up to 24 months.9108,9113

    SAMe may have an additive effect on drugs that increase serotonin levels.5231,5232 Serotonin syndrome has been reported with concurrent use of SAMe and the TCA clomipramine (Anafranil).3521 Tell patients not to combine SAMe with other antidepressants.

    Chemically, SAMe is notoriously unstable. Several oral salt forms of SAMe are available...sulfate, sulfate-p-toluenesulfonate (also labeled as tosylate), and butanedisulfonate.5231,5444 Tell patients to look for the butanedisulfonate salt...it's the most bioavailable and seems to be the most stable.5446,9110

    SAMe is expensive. It can cost more than $150 per month for doses commonly used to treat depression... 800 mg BID.5189 This is more than the cost of newer antidepressants. Tell patients SAMe might help depression, but it's extremely expensive.

    Inositol is a naturally occurring isomer of glucose. Inositol is sometimes called vitamin B8, but it's NOT actually a vitamin. Inositol works differently than other antidepressants. Rather than increase neurotransmitter levels as most antidepressants do, inositol plays a supporting role in cellular communication. It relays messages from serotonin, norepinephrine, and cholinergic receptors.10850

    There's preliminary evidence that taking high-dose inositol 12 grams per day for 4 weeks might help depression.2185 But this benefit goes away rapidly when it's stopped.2026 Inositol is well-tolerated. But there's not enough evidence yet to recommend it.

    NADH, the reduced form of nicotinamide adenine dinucleotide, is also recommended for depression. It might increase dopamine levels.3091 But there's no reliable clinical research to support its use.
     
    View brands containing:
    -St. John's Wort
      Question #2
    Antidepressant activity of St. John's wort is NOW thought to be due to which of the following?
  •   Question #3
    A concern in the use of St. John's wort is
  • View brands containing:
    -S-adenosyl-methionine (SAMe)
      Question #4
    The most stable and bioavailable salt of SAMe is
  •   Question #5
    Which of the following is TRUE?
  • View brands containing:
    -Inositol
    -NADH
    Neurotransmitter Precursorsreturn to top 

    Phenylalanine is an amino acid precursor of tyrosine, which is a precursor to the neurotransmitters dopamine and norepinephrine. Tyrosine increases neurotransmitter levels.9931 This may contribute to an antidepressant effect. A phenylalanine/tyrosine free diet elicits symptoms of depression in non-depressed patients.10852

    Limited clinical research suggests phenylalanine might be useful for depression.2468,2469 Tyrosine doesn't seem to have any effect on MODERATE depression.7208 There's interesting research about phenylalanine for treating depression, but it's too soon to recommend it.

    Phenylalanine should be avoided in people with inherited disorders of phenylalanine metabolism, such as phenylketonuria and alkaptonuria.2084,10754 Phenylalanine in patients with schizophrenia or taking neuroleptics can exacerbate tardive dyskinesia.2457,2458 Phenylalanine and levodopa can exacerbate tremor, rigidity, and the "on-off" syndrome in patients with Parkinson's disease.3291,3294 Tell patients with these conditions not to use phenylalanine.

    L-tryptophan and 5-hydroxytryptophan (5-HTP) are precursors of serotonin. Taking these supplements might help for depression. But there are concerns about safety.

    The largest safety concern for L-tryptophan and 5-HTP is potentially fatal eosinophilia-myalgia syndrome (EMS). In 1989, more than 1500 cases of EMS and 37 deaths were associated with L-tryptophan use in the U.S. Ninety-five percent of all EMS cases were traced to a single international manufacturer. In 1990, FDA limited the importation of all over-the-counter L-tryptophan products.7067 L-tryptophan has not been proven to be the cause of EMS. EMS may have been caused by one of several impurities.8051,10289 Similar impurities have been isolated in 5-HTP products.10084 The long-term safety of L-tryptophan and 5-HTP is unknown.

    Tryptophans, especially 5-HTP, might improve depressive symptoms. But the optimal dose is unknown.10857,10858 Information on long term safety is also lacking. Until the questions of EMS and long-term safety are resolved, tell patients not to use L-tryptophan or 5-HTP for depression.

    Some research suggests phosphatidylserine and acetyl-L-carnitine might relieve depressive symptoms in elderly patients.3603,3604,7113 Preclinical research suggests phosphatidylserine increases norepinephrine and dopamine levels. But this does not appear to occur in humans.7113 Preliminary research suggests that acetyl-L-carnitine may enhance synaptic transmission.10395 But it's too soon to recommend either phosphatidylserine or acetyl-L-carnitine for depression.

     
    View brands containing:
    -Phenylalanine
    -Tyrosine
    View brands containing:
    -L-Tryptophan
    -5-hydroxy-
    tryptophan (5-HTP)
      Question #6
    Concerns about L-tryptophan and 5-HTP include:
  • View brands containing:
    -Phosphatidylserine
    -Acetyl-L-Carnitine
    Omega-3 Fatty Acidsreturn to top 

    The omega-3 fatty acids, docosahexanoic acid (DHA) and eicosapentaenoic acid (EPA), are essential polyunsaturated fatty acids (PUFAs). DHA is the predominant omega-3 fatty acid in the brain. DHA is required for optimal neuronal function.10866

    Researchers theorize that omega-3s might normalize membrane structure in the brain. Omega-3s might also improve neurotransmitter uptake.10870,10871 Low omega-3 levels in plasma and red blood cells are associated with depression.10859,10860,10866

    DHA alone doesn't seem to have any significant effect on depression.10869 But omega-3 fatty acids might have a role as ADJUNCT agents in depression. Several studies suggest that either combination DHA/EPA supplements or EPA alone can reduce depressive symptoms in patients already using conventional antidepressants.10866,10871,10872

    Doses of greater than 3 grams per day of omega-3s are often used for adjunctive treatment of depression. These doses can inhibit platelet aggregation, cause bleeding, and potentially increase the risk for hemorrhagic stroke.1313,7603,8699 Theoretically, omega-3 supplements might have an additive effect with anticoagulant drugs. However, some research suggests that doses of 3 to 6 grams per day might not have a significant effect on coagulation in patients taking warfarin (Coumadin).8801

    Tell patients taking conventional antidepressants that omega-3 fatty acids might help. Remind patients to inform ALL healthcare providers that they are taking omega-3 fatty acids. It's important to be aware of the increased bleeding risk.

     
    View brands containing:
    -Omega-3 fatty
    acids
    -Docosahexaenoic
    acid (DHA)
    -Eicosapentaenoic
    acid (EPA)
      Question #7
    Omega-3 fatty acids at doses greater than 3 grams per day may increase the risk of
  • Hormonal Agentsreturn to top 

    Dehydroepiandrosterone (DHEA) is an endogenous steroid hormone. DHEA is metabolized to androstenedione, the major precursor to androgens and estrogens. DHEA levels are higher in men than in women, and naturally decline with age in both sexes.8597

    Theories about how DHEA might work for depression are vague. DHEA levels in depressed patients can be higher, lower, or the same as non-depressed patients.10874,10875,10876,10877 Elderly people with depression seem to have lower levels of DHEA following successful treatment of depression.

    DHEA is possibly safe to use short-term, but the safety of long-term or high dose DHEA is unknown. Relatively low doses (50-100 mg per day) can cause DHEA to rise above physiological levels.4251 DHEA is a potent estrogen agonist. It causes the growth of estrogen-receptor positive breast cancer cells. DHEA can overcome the estrogen receptor antagonist action of conventional medications like fulvestrant (Faslodex).10370 People at risk for hormone-sensitive cancer and other hormone-sensitive conditions should avoid DHEA.

    There's evidence DHEA helps depression in some patients.3270,4233 But there isn't enough evidence to recommend it. There are also concerns about its safety. Tell patients not to use DHEA for depression.

    Other endogenous hormones such as pregnenolone and progesterone are sometimes suggested for treatment of depression. But there's no reliable research to support their use.



     
    View brands containing:
    -Dehydroepi-
    androsterone
    (DHEA)
      Question #8
    Which of these statements about DHEA for depression is TRUE?
  • View brands containing:
    -Pregnenolone
    -Progesterone
    Nutrientsreturn to top 

    Depression is sometimes blamed on vitamin deficiency. There's no evidence that multivitamins or vitamin C are useful for treating depression. Some very preliminary research suggests varying efficacy of B vitamins. But it's too early to recommend vitamin supplements for treating depression.10888,10889

    Folic acid is required for the production of neurotransmitters including serotonin.10884,10885 Folic acid deficiency is common among patients with depression.10879,10880,10881 People with low folate status or lower dietary folate intake have a higher risk for depression.10882,10883 Lower folate levels also link to poor response rates for patients taking antidepressants.6239,10880

    Limited clinical research suggests that folic acid is NOT effective as a replacement for conventional antidepressant therapy.10886 But commonly used folic acid doses of 500 mcg per day might be effective when used in addition to conventional antidepressants, especially in women.3657,10884,10887

    At doses less than 1000 mcg per day, folic acid is associated with few side effects. Folic acid therapy can mask vitamin B12 deficiency and allow progression of neurological damage. Check patients' vitamin B12 status before starting folic acid therapy.6243

    There's no evidence that taking folic acid prevents depression. If patients ask about folate supplementation, suggest foods high in folates...citrus fruits, dark leafy vegetables, and folate-fortified cereals and grains. It's too early to recommend folate for treating depression.

     
    View brands containing:
    -Vitamin C
    -Folic acid
      Question #9
    Folic acid can

  • Miscellaneousreturn to top 

    Other natural products such as damiana, ginkgo, glutamine, lavender, turmeric, and yohimbe are sometimes tried for depression. But research is too preliminary to recommend them.

    Practice Pearl

    Tell patients not to use Ginkgo biloba to treat the sexual side effects of SSRIs. More than one third of patients on SSRIs experience sexual dysfunction.10892 Ginkgo doesn't help for SSRI induced sexual dysfunction.207,3966,10893 Steer patients away from ginkgo to drugs such as sildenafil (Viagra) that appear to be useful in SSRI-induced sexual dysfunction.10894

     

     
    View brands containing:
    -Damiana
    -Ginkgo
    -Glutamine
    -Lavender
    -Turmeric
    -Yohimbe
    The Bottom Linereturn to top 

    St. John's wort has been extensively studied for its effects on depression. Compared with other natural products, it is extremely well-researched in terms of pharmacology. St. John's wort appears to be effective for MILD and MODERATE depression with relatively few adverse effects.

    For patients not taking interacting medications, St. John's wort may be a reasonable choice for MILD and MODERATE depression. Refer patients with SEVERE depression to a mental health specialist. St. John's wort is not effective for SEVERE depression.

    S-adenosylmethionine (SAMe) is not as well studied as St. John's wort...but it seems safer in terms of drug interactions. SAMe is extremely expensive when taken in antidepressant doses. Tell patients to wait for more definitive studies and lower cost formulations.

    The serotonin precursors L-tryptophan and 5-HTP might be useful as add-ons to conventional antidepressant therapy. But until the issue of eosinophilia-myalgia causing impurities is resolved, these supplements should be avoided.

    Omega-3 fatty acids show promise as adjunctive treatments with conventional antidepressants. Explain the increased risk of bleeding to patients and the importance of telling all healthcare providers about omega-3 use.

    Steer patients away from dehydroepiandrosterone (DHEA). The evidence for antidepressant effect is weak and the long-term risks are unknown.

    Supplemental folic acid looks promising as an additive to conventional antidepressants in patients likely to be folate deficient. Taking a folic acid-containing multivitamin and/or increasing dietary intake of folate may be helpful.

    Emphasize to patients the importance of telling ALL healthcare providers about the natural products they're taking. Many natural products (e.g., St. John's wort, SAMe, L-tryptophan) can have an additive effect on drugs with serotonin or monamine oxidase activity. Serotonin syndrome and hypertensive crisis can result.


     
      Question #10
    Which of these natural medicines might help as an adjunct to conventional antidepressants?
  •   
     
    Recommendation Chart for Natural Medicines Used for Depression *
    Safety/EffectiveLikely
    Safe
    Possibly
    Safe
    Insufficient
    Evidence
    Possibly
    Unsafe
    Likely
    Unsafe
    Unsafe
    Effective      
    Likely
    Effective
    -St. John's
    Wort
     
         
    Possibly
    Effective
    -SAMe
    -Omega-3
    fatty acids
    (Fish oils)
    -Folic acid
     
      
    -5-HTP
     
      
    Insufficient
    Evidence
    -Proges-
    terone
    -Vitamin C
     
    -NADH
    -Phenyl-
    alanine
    -Phospha-
    tidylserine
    -Acetyl-L-
    carnitine
    -Damiana
    -Glutamine
    -Lavender
    -DHEA*
     
    -Pregne-
    nolone
     
    -DHEA*
     
    -Yohimbe
     
    -L-Trypto-
    phan
     
    Possibly
    Ineffective
    -Ginkgo
     
    -Inositol
     
        
    Likely
    Ineffective
          
    Ineffective      
     KEY:
     Consider recommending this product.
     Don't recommend using this product.
     Recommend against using this product.

    * These proposed recommendations are based solely on the Safety and Effectiveness Ratings contained in Natural Medicines Comprehensive Database. This assumes use of high-quality, uncontaminated products and the use of typical doses. Keep in mind that some products are never appropriate for some patients due to concomitant disease states, potential drug interactions, or other clinical factors. Use your clinical judgment before recommending any product.

    References return to top
    207Ashton AK, Ahrens K, Gupta S, Masand PS. Antidepressant-induced sexual dysfunction and Ginkgo biloba. Am J Psychiatry 2000;157:836-7.
    542Gordon JB. SSRIs and St. John's Wort: possible toxicity? Am Fam Physician 1998;57:950, 953.
    763Muller WE, Singer A, Wonnemann M, et al. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacopsychiatry 1998;31:16-21.
    1292Yue QY, Bergquist C, Gerden B. Safety of St. John's wort (Hypericum perforatum). Lancet 2000;355:576-7.
    1313FDA. Center for Food Safety and Applied Nutrition. Letter regarding dietary supplement health claim for omega-3 fatty acids and coronary heart disease. Available at: http://vm.cfsan.fda.gov/~dms/ds-ltr11.html.
    1340Durr D, Stieger B, Kullak-Ublick GA, et al. St. John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000;68:598-604.
    2026Levine J, Barak Y, Kofman O, Belmaker RH. Follow-up and relapse analysis of an inositol study of depression. Isr J Psychiatry Relat Sci 1995;32:14-21.
    2084Zhao G. [Inherited metabolic aberration of phenylalanine in the family members of patients with essential hypertension and stroke]. [Article in Chinese]. Chung Hua I Hsueh Tsa Chih (Taipei) 1991;71:28, 388-90.
    2185Levine J, Barak Y, Gonzalves M, et al. Double-blind, controlled trial of inositol treatment of depression. Am J Psychiatry 1995;152:792-4.
    2457Mosnik DM, Spring B, Rogers K, Baruah S. Tardive dyskinesia exacerbated after ingestion of phenylalanine by schizophrenic patients. Neuropsychopharmacology 1997;16:136-46.
    2458Gardos G, Cole JO, Matthews JD, et al. The acute effects of a loading dose of phenylalanine in unipolar depressed patients with and without tardive dyskinesia. Neuropsychopharmacology 1992;6:241-7.
    2468Beckmann H, Athen D, Olteanu M, Zimmer R. DL-phenylalanine versus imipramine: a double-blind controlled study. Arch Psychiatr Nervenkr 1979;227:49-58.
    2469Birkmayer W, Riederer P, Linauer W, Knoll J. L-deprenyl plus L-phenylalanine in the treatment of depression. J Neural Transm 1984;59:81-7.
    3091Vrecko K, Storga D, Birkmayer JG, et al. NADH stimulates endogenous dopamine biosynthesis by enhancing the recycling of tetrahydrobiopterin in rat phaeochromocytoma cells. Biochim Biophys Acta 1997;1361:59-65.
    3270Wolkowitz OM, Reus VI, Keebler A, et al. Double-blind treatment of major depression with dehydroepiandosterone. Am J Psychiatry 1999;156:646-9.
    3291Nutt JG, Woodward WR, Hammerstad JP, et al. The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N Engl J Med 1984;310:483-8.
    3294Eriksson T, Granerus AK, Linde A, et al. "On-off" phenomenon in Parkinson's disease: relationship between dopa and other large neutral amino acids in plasma. Neurology 1988;38:1245-8.
    3521Iruela LM, Minguez L, Merino J, Monedero G. Toxic interaction of S-adenosylmethionine and clomipramine. Am J Psychiatry 1993;150:522.
    3548Kim HL, Streltzer J, Goebert D. St. John's wort for depression: A meta analysis of well-defined clinical trials. J Nerv Ment Dis 1999;187:532-9.
    3549Linde K, Ramirez G, Mulrow CD, et al. St. John's wort for depression: an overview and meta-analysis of randomized clinical trials. BMJ 1996;313:253-8.
    3550Harrer G, Schmidt U, Kuhn U, Biller A. Comparison of equivalence between the St. John's wort extract LoHyp-57 and fluoxetine. Arzneimittelforschung 1999;49:289-96.
    3551Philipp M, Kohnen R, Hiller KO. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomized mulicentre study of treatment for eight weeks. BMJ 1999;319:1534-9.
    3556Nebel A, Schneider BJ, Baker RA, et al. Potential metabolic interaction between St. John's wort and theophylline. Ann Pharmacother 1999;33:502.
    3599Markowitz JS, DeVane CL, Boulton DW, et al. Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci 2000;66:PL 133-9.
    3603Garzya G, Corallo D, Fiore A, et al. Evaluation of the effects of L-acetylcarnitine on senile patients suffering from depression. Drugs Exp Clin Res 1990;16:101-6.
    3604Tempesta E, Casella L, Pirrongelli C, et al. L-acetylcarnitine in depressed elderly subjects. A cross-over study vs placebo. Drugs Exp Clin Res 1987;13:417-23.
    3657Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J Affect Dis 2000;60:121-31.
    3966Balon R. Ginkgo biloba for antidepressant-induced sexual dysfunction? J Sex Marital Ther 1999;25:1-2.
    4233Wolkowitz OM, Reus VI, Manfredi F, et al. Dehydroepiandrosterone (DHEA) treatment of depression. [Abstract] Biol Psychiatry 1997;41:311-8.
    4251Morales AJ, Haubrich RH, Hwang JY, et al. The effect of six months treatment with 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. [Abstract] Clin Endocrinol (Oxf)1998;49:421-32.
    4521Jensen AG, Hansen SH, Nielsen EO. Adhyperforin as a contributor to the effect of Hypericum perforatum L. in biochemical models of antidepressant activity. Life Sci 2001;68:1593-605.
    4835Wang Z, Gorski JC, Hamman MA, et al. The effects of St. John's wort (Hyericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001;70:317-26.
    4897Schrader E. Equivalence of St. John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int Clin Psychopharmacol 2000;15:61-8.
    4899Linde K, Mulrow CD. St. John's wort for depression. Cochrane Database Syst Rev 2000;(2):CD000448.
    5096Shelton RC, Keller MB, Gelenberg A, et al. Effectiveness of St. John's wort in major depression: A randomized, placebo-controlled trial. JAMA 2001;285:1978-86.
    5189Bressa GM. S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand Suppl 1994;154:7-14.
    5192Salmaggi P, Bressa GM, Nicchia G, et al. Double-blind, placebo-controlled study of S-adenosyl-L-methionine in depressed postmenopausal women. Psychother Psychosom 1993;59:34-40.
    5193Berlanga C, Ortega-Soto HA, Ontiveros M, Senties H. Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipramine. Psychiatry Res 1992;44:257-62.
    5195Kagan BL, Sultzer DL, Rosenlicht N, Gerner RH. Oral S-adenosylmethionine in depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 1990;147:591-5.
    5196Rosenbaum JF, Fava M, Falk WE, et al. The antidepressant potential of oral S-adenosyl-l-methionine. Acta Psychiatr Scand 1990;81:432-6.
    5200Bell KM, Plon L, Bunney WE Jr, Potkin SG. S-adenosylmethionine treatment of depression: a controlled clinical trial. Am J Psychiatry 1988;145:1110-4.
    5231Friedel HA, Goa KL, Benfield P. S-adenosyl-L-methionine. A review of its pharmacological properties and therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism. Drugs 1989;38:389-416.
    5232Bottiglieri T, Hyland K, Reynolds EH. The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders. Drugs 1994;48:137-52.
    5444Cowley G, Underwood A. Newsweek. July 5, 1999; pp. 46-50.
    5446Czap A. Beware the son of SAMe. Altern Med Rev 1999;4:73.
    6201Brown TM. Acute St. John's wort toxicity. Am J Emerg Med 2000;18:231-2.
    6239Fava M, Borus JS, Alpert JE, et al. Folate, vitamin B12, and homocysteine in major depressive disorder. Am J Psychiatry 1997;154:426-8.
    6243Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline (2000). Washington, DC: National Academy Press, 2000. Available at: http://books.nap.edu/books/0309065542/html/.
    6400Brenner R, Azbel V, Madhusoodanan S, et al. Comparison of an extract of Hypericum (LI 160) and sertraline in the treatment of depression: A double-blind, randomized pilot study. Clin Ther 2000;22:411-9.
    6428Williams JW, Mulrow CD, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: Evidence report summary. Ann Intern Med 2000;132:743-56.
    6434Woelk H. Comparison of St. John's wort and imipramine for treating depression: randomized controlled trial. BMJ 2000;321:536-9.
    7067FDA. Information paper on L-tryptophan and 5-hydroxy-L-tryptophan. Office of Nutritional Products, Labeling, Dietary Supplements. Center for Food Safety and Applied Nutrition. February 2001.
    7113Maggioni M, Picotti GB, Bondiolotti GP, et al. Effects of phosphatidylserine therapy in geriatric patients with depressive disorders. Acta Psychiatr Scand 1990;81:265-70.
    7208Gelenberg AJ, Wojcik JD, Falk WE, et al. Tyrosine for depression: a double-blind trial. J Affect Disord 1990;19:125-32.
    7603Caicoya M. Fish consumption and stroke: a community case-control study in Asturias, Spain. Neuroepidemiology 2002;21:107-14.
    7809Gorski JC, Hamman MA, Wang Z, et al. The effect of St. John's wort on the efficacy of oral contraceptives (abstract MPI-80). Clin Pharmacol Ther 2001;71:P25.
    7810Hennessy M, Kelleher D, Spiers JP, et al. St Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol 2002;53:75-82.
    7812Patel S, Robinson R, Burk M. Hypertensive crisis associated with St. John's Wort. Am J Med 2002;112:507-8.
    8051Shapiro S. L-tryptophan and eosinophilia-myalgia syndrome. Lancet 1994;344:817-9.
    8597Mazat L, Lafont S, Berr C, et al. Prospective measurements of dehydroepiandrosterone sulfate in a cohort of elderly subjects: relationship to gender, subjective health, smoking habits, and 10-year mortality. Proc Natl Acad Sci U S A 2001;98:8145-50.
    8699Pedersen HS, Mulvad G, Seidelin KN, et al. N-3 fatty acids as a risk factor for haemorrhagic stroke. Lancet 1999;353:812-3.
    8801Bender NK, Kraynak MA, Chiquette E, et al. Effects of marine fish oils on the anticoagulation status of patients receiving chronic warfarin therapy. J Thromb Thrombolysis 1998;5:257-61.
    8936Calapai G, Crupi A, Firenzuoli F, et al. Serotonin, norepinephrine and dopamine involvement in the antidepressant action of hypericum perforatum. Pharmacopsychiatry 2001;34:45-9.
    9108Hardy M, Coulter I, Morton SC, et al. S-Adenosyl-L-Methionine for Treatment of Depression, Osteoarthritis, and Liver Disease. Evidence Report/Technology Assessment Number 64. Agency for Healthcare Research and Quality, US Dept of Health and Human Services; 2002. AHRQ publication 02-E033. Rockville, Md. Available at: http://www.ahrq.gov/clinic/tp/sametp.htm.
    9109Delle Chiaie R, Pancheri P, Scapicchio P. Efficacy and tolerability of oral and intramuscular S-adenosyl-Lmethionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in multicenter studies. Am J Clin Nutr 2002;76:1172S-6S.
    9110Bottiglieri T. S-Adenosyl-L-methionine (SAMe): from the bench to the bedside--molecular basis of a pleiotrophic molecule. Am J Clin Nutr 2002;76:1151S-7S.
    9113Mischoulon D, Fava M. Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. Am J Clin Nutr 2002;76:1158S-61S.
    9880Schwarz UI, Buschel B, Kirch W. Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception. Br J Clin Pharmacol 2003;55:112-3.
    9931Aquilani R, Iadarola P, Boschi F, et al. Reduced plasma levels of tyrosine, precursor of brain catecholamines, and of essential amino acids in patients with severe traumatic brain injury after rehabilitation. Arch Phys Med Rehabil 2003;84:1258-65.
    10084Johnson KL, Klarskov K, Benson LM, et al. Presence of peak X and related compounds: the reported contaminant in case related 5-hydroxy-L-tryptophan associated with eosinophilia-myalgia syndrome. J Rheumatol 1999;26:2714-7.
    10289Simat TJ, Kleeberg KK, Muller B, Sierts A. Synthesis, formation, and occurrence of contaminants in biotechnologically manufactured L-tryptophan. Adv Exp Med Biol 1999;467:469-80.
    10370Calhoun KE, Pommier RF, Muller P, et al. Dehydroepiandrosterone sulfate causes proliferation of estrogen receptor-positive breast cancer cells despite treatment with fulvestrant. Arch Surg 2003;138:879-83.
    10395Pettegrew JW, Levine J, McClure RJ. Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression. Mol Psychiatry 2000;5:616-32.
    10754National Institutes of Health Consensus Development Conference Statement. Phenylketonuria: Screening and Management http://odp.od.nih.gov/consensus/cons/113/113_statement.htm (Accessed 15 August 2003).
    10830Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St. John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003;290:1500-4.
    10831Whooley MA, Simon GE. Managing depression in medical outpatients. N Engl J Med 2000;343:1942-50.
    10832Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-105.
    10833Remick RA. Diagnosis and management of depression in primary care: a clinical update and review. CMAJ 2002;167:1253-60.
    10834Bostwick JM, Pankratz VS. Affective disorders and suicide risk: a reexamination. Am J Psychiatry 2000;157:1925-32.
    10835Ruo B, Rumsfeld JS, Hlatky MA, et al. Depressive symptoms and health-related quality of life: the Heart and Soul Study. JAMA 2003;290:215-21.
    10841Kessler RC, Soukup J, Davis RB, et al. The use of complementary and alternative therapies to treat anxiety and depression in the United States. Am J Psychiatry 2001;158:289-94.
    10842Knaudt PR, Connor KM, Weisler RH, et al. Alternative therapy use by psychiatric outpatients. J Nerv Ment Dis 1999;187:692-5.
    10843Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St. John's wort) in major depressive disorder: a randomized controlled trial. JAMA 2002;287:1807-14.
    10845Hammerness P, Basch E, Ulbricht C, et al. St. John's wort: a systematic review of adverse effects and drug interactions for the consultation psychiatrist. Psychosomatics 2003;44:271-82.
    10847Gurley BJ, Gardner SF, Hubbard MA, et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 2002;72:276-87.
    10848Foster BC, Vandenhoek S, Hana J, et al. In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. Phytomedicine 2003;10:334-42.
    10850Benjamin J, Agam G, Levine J, et al. Inositol treatment in psychiatry. Psychopharmacol Bull 1995;31:167-75.
    10852McLean A, Rubinsztein JS, Robbins TW, Sahakian BJ. The effects of tyrosine depletion in normal healthy volunteers: implications for unipolar depression. Psychopharmacology (Berl) 2004;171:286-97.
    10857van Praag HM. Management of depression with serotonin precursors. Biol Psychiatry 1981;16:291-310.
    10858Byerley WF, Judd LL, Reimherr FW, Grosser BI. 5-Hydroxytryptophan: a review of its antidepressant efficacy and adverse effects. J Clin Psychopharmacol 1987;7:127-37.
    10859Maes M, Christophe A, Delanghe J, et al. Lowered omega3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res 1999;85:275-91.
    10860Tiemeier H, van Tuijl HR, Hofman A, et al. Plasma fatty acid composition and depression are associated in the elderly: the Rotterdam Study. Am J Clin Nutr 2003;78:40-6.
    10866Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 2002;59:913-9.
    10869Marangell LB, Martinez JM, Zboyan HA, et al. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry 2003;160:996-8.
    10870Rapoport SI, Bosetti F. Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder? Arch Gen Psychiatry 2002;59:592-6.
    10871Su KP, Huang SY, Chiu CC, Shen WW. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol 2003;13:267-71.
    10872Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 2002;159:477-9.
    10874Tollefson GD, Haus E, Garvey MJ, et al. 24 hour urinary dehydroepiandrosterone sulfate in unipolar depression treated with cognitive and/or pharmacotherapy. Ann Clin Psychiatry 1990;2:39-45.
    10875Legrain S, Berr C, Frenoy N, et al. Dehydroepiandrosterone sulfate in a long-term care aged population. Gerontology 1995;41:343-51.
    10876Barrett-Connor E, von Muhlen D, Laughlin GA, Kripke A. Endogenous levels of dehydroepiandrosterone sulfate, but not other sex hormones, are associated with depressed mood in older women: the Rancho Bernardo Study. J Am Geriatr Soc 1999;47:685-91.
    10877Morrison MF, Katz IR, Parmelee P, et al. Dehydroepiandrosterone sulfate (DHEA-S) and psychiatric and laboratory measures of frailty in a residential care population. Am J Geriatr Psychiatry 1998;6:277-84.
    10879Bottiglieri T, Laundy M, Crellin R, et al. Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry 2000;69:228-32.
    10880Alpert M, Silva RR, Pouget ER. Prediction of treatment response in geriatric depression from baseline folate level: interaction with an SSRI or a tricyclic antidepressant. J Clin Psychopharmacol 2003;23:309-13.
    10881Tiemeier H, van Tuijl HR, Hofman A, et al. Vitamin B12, folate, and homocysteine in depression: the Rotterdam Study. Am J Psychiatry 2002;159:2099-101.
    10882Morris MS, Fava M, Jacques PF, et al. Depression and folate status in the US Population. Psychother Psychosom 2003;72:80-7.
    10883Tolmunen T, Voutilainen S, Hintikka J, et al. Dietary folate and depressive symptoms are associated in middle-aged Finnish men. J Nutr 2003;133:3233-6.
    10884Taylor MJ, Carney S, Geddes J, Goodwin G. Folate for depressive disorders. Cochrane Database Syst Rev 2003;(2):CD003390.
    10885Coppen A, Swade C, Jones SA, et al. Depression and tetrahydrobiopterin: the folate connection. J Affect Disord 1989;16:103-7.
    10886Passeri M, Cucinotta D, Abate G, et al. Oral 5'-methyltetrahydrofolic acid in senile organic mental disorders with depression: results of a double-blind multicenter study. Aging (Milano) 1993;5:63-71.
    10887Godfrey PS, Toone BK, Carney MW, et al. Enhancement of recovery from psychiatric illness by methylfolate. Lancet 1990;336:392-5.
    10888Bell IR, Edman JS, Morrow FD, et al. Brief communication. Vitamin B1, B2, and B6 augmentation of tricyclic antidepressant treatment in geriatric depression with cognitive dysfunction. J Am Coll Nutr 1992;11:159-63.
    10889Oren DA, Teicher MH, Schwartz PJ, et al. A controlled trial of cyanocobalamin (vitamin B12) in the treatment of winter seasonal affective disorder. J Affect Disord 1994;32:197-200.
    10892Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002;63:357-66.
    10893Kang BJ, Lee SJ, Kim MD, Cho MJ. A placebo-controlled, double-blind trial of Ginkgo biloba for antidepressant-induced sexual dysfunction. Hum Psychopharmacol 2002;17:279-84.
    10894Nurnberg HG, Hensley PL, Gelenberg AJ, et al. Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. JAMA 2003;289:56-64.
    11154Shelton RC. St John's Wort for the treatment of depression. Lancet Neurol 2002;1:275.
    Back to Clinical Management Series